Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 1014-1019

  Litwin, Alain H ^a   Soloway, Irene J ^a   Cockerham Colas, Lauren ^a   Reynoso, Sheila ^a   Heo, Moonseong ^a   Tenore, Christopher ^a   Roose, Robert J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Direct acting antiviral agents; HCV; IDU; Injection drug users; PWID; PWUD

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; INTERLEUKIN 28B; OPIATE AGONIST; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ANXIETY DISORDER; ARTICLE; BLOOD TRANSFUSION; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DRUG ABUSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; IL28B GENE; LIVER CIRRHOSIS; MALE; MENTAL DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; HEPATITIS C, CHRONIC; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84941802232     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.08.008     Document Type: Article

References (30)

1. AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015, 62:932-954. 10.1002/hep.27950.
2. Akiyama M.J., Piotrowski J.I., Roytman M.M., Chan S.M., Hong L.K., Huddleston L., et al. New triple therapy for chronic hepatitis C: Real life clinical experience in a community setting. Hawaii Journal of Medicine and Public Health 2013, 72(9 Suppl. 4):6-13.
3. Alavi M., Raffa J.D., Deans G.D., Lai C., Karjden M., Dore G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 2014, 34(8):1198-1206.
4. Aspinall E., Corson S., Doyle J., Grebely J., Hutchinson S.J., Dore G.J., et al. Peginterferon and ribavirin treatment for chronic hepatitis C in people who inject drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2012, 57(Suppl. 2):S80-S89.
5. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364(13):1207-1217.
6. Barua S., Greenwald R., Grebely J., Dore G.J., Swan T., Taylor L.E. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 2015, 163(August (3)):215-223.
7. Buti M., Agarwal K., Horsmans Y., Sievert W., Janczewska E., Zeuzem S., et al. Telaprevir twice daily is noninferior to telaprevir every 8hours for patients with chronic hepatitis C. Gastro 2014, 146(3):744-753.
8. Davis G.L., Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine 2001, 345:215-217.
9. Dimova R.B., Zeremski M., Jacobson I.M., Hagan H., Des Jarlais D.C., Talal A.H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2013, 56(6):806-816.
10. EASL EASL recommendations on treatment of hepatitis C 2015. Journal of Hepatology 2015, 63:199-236.
11. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment from hepatitis C from illicit drug-users?. New England Journal of Medicine 2001, 345:211-214.
12. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4):433-444.
13. Grebely J., Robaeys G., Bruggmann P., Aghemo A., Backmund M., Bruneau J., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015, 26:1028-1038.
14. Grebely J., Raffa J.D., Lai C. Low uptake of treatment of hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 2009, 16:352-358.
15. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 2009, 49(4):561-573.
16. Iversen J., Grebely J., Topp L., Wand H., Dore G., Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. Journal of Viral Hepatitis 2014, 21(3):198-207.
17. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 2011, 364(25):2405-2416.
18. Kalichman S.C., Amaral C.M., Swetzes C., Jones M., Macy R., Kalichman M.O., et al. A simple single-item rating scale to measure medication adherence: Further evidence for convergent validity. Journal of the International Association of Physicians in AIDS Care 2009, 8(6):367-374.
19. Litwin A.H., Harris K.A., Nahvi S., Zamor P.J., Soloway I.J., Tenore P.L., et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2009, 37(1):32-40.
20. Litwin A.H., Soloway I., Gourevitch M.N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases 2005, 40:S339-S345.
21. Martel-Laferriere V., Brinkley S., Bichoupan K., Posner S., Stivala A., Prumalswami P., et al. On-treatment and sustained virologic response rates of telaprevir-based HCV treatments do not differ between HIV/HCV co-infected and HCV mono-infected patients 2013, Program and abstracts of the International Conference on Viral Hepatitis 2013, March 25-26, 2013, New York, NY, Abstract 31. http://iapac.org/icvh/presentations/ICVH2013_OA31.pdf.
22. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Dienstag J., et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002, 123(4):1061-1069.
23. Moorjani H., Koenigsmann C., Kim M.J., Spaulding A.C. Prisoners treated for hepatitis C with protease inhibitor. Emerging Infectious Diseases 2015, (cited February 17, 2015). 10.3201/eid2101.141025.
24. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378(9791):571-583.
25. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364(13):1195-1206.
26. Stein M.R., Soloway I.J., Jefferson K.S., Roose R.J., Arnsten J.H., Litwin A.H. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 2012, 43(4):424-432.
27. Sterling R.K., Kuo A., Rustgi V.K., Sulkowski M.S., Stewart T.G., Fenkel J.M., et al. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Alimentary Pharmacology & Therapeutics 2015, 41:671-685.
28. WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, World Health Organization, Geneva, Switzerland.
29. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and cost in the United States. American Journal of Public Health 2000, 90(10):1562-1569.
30. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364(25):2417-2428.